| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2546063 | Journal of Ethnopharmacology | 2009 | 8 Pages |
GoalsDiabetic nephropathy (DN) has long been recognized as the leading cause of end-stage renal disease. Recent experimental studies have shown that Astragalus membranaceus (AM) (root) has an inhibitory effect on the oxidative stress that characterizes early DN. This systematic review assesses the efficacy and safety of AM (root), used as a single herb, in slowing the progression of DN in diabetic rat models.MethodsWe conducted both an electronic search and a search by hand of randomized, controlled AM (root) treatment studies (including its effective components) focusing on animal models of DN. Two reviewers independently selected and assessed the studies.ResultsAmong the 41 articles identified, 13 reports that fulfilled the inclusion criteria were included. Significant beneficial effects were observed in the AM (root) treated groups compared to controls regarding fasting blood glucose levels (standardized mean difference [SMD]: −2.86, 95% confidential interval (CI): −4.26, −1.46, P < 0.001), glomerular filtration rate (SMD: −3.36, 95% CI: −4.69, −2.03, P < 0.00001), urinary albumin excretion rate (SMD: −2.46, 95% CI: −3.75, −1.16, P = 0.0002), and thickness of the glomerular basement membrane (SMD: −3.51, 95% CI: −6.68, −0.34, P = 0.03).ConclusionsAM (root) and its effective components are effective in reducing fasting blood glucose and albuminuria levels, in reversing the glomerular hyperfiltration state, and in ameliorating the pathological changes of early DN in rat models.
Graphical abstractSignificant beneficial effects of Astragalus membranaceus (root) in reversing early diabetic nephropathy and glucose control were observed in animal models in systematic review.Figure optionsDownload full-size imageDownload as PowerPoint slide
